KEY vs SGMO · P/E 13, rev $7.51B vs rev $57.8M
KeyCorp (KEY) versus Sangamo Therapeutics Inc (SGMO) — a side-by-side from cached financials, not a winner call.
KeyCorp (KEY) is a banks - regional company listed on US.
Sangamo Therapeutics Inc (SGMO) is a biotechnology company listed on NASDAQ.
Latest reported KEY revenue for 2025-12-31 was $7.51B. Net income was $1.83B. Revenue was up 62.7% from 2024-12-31 to 2025-12-31. KEY currently screens at market cap $22.64B and trailing P/E 12.8.
Latest reported SGMO revenue for 2024-12-31 was $57.8M. Net income was -$97.9M. Revenue was down 67.2% from 2023-12-31 to 2024-12-31. SGMO currently screens at market cap $74.6M.
KEY currently screens at market cap $22.64B and trailing P/E 12.8. SGMO currently screens at market cap $74.6M.
Not investment advice. Open the KEY and SGMO stock pages for the full models.
Not investment advice.